Tenon Medical, Inc. (TNON)
NASDAQ: TNON · Real-Time Price · USD
0.3500
-0.2521 (-41.87%)
At close: Jun 18, 2026, 4:00 PM EDT
0.6400
+0.2900 (82.86%)
After-hours: Jun 18, 2026, 7:59 PM EDT
Company Description
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States.
The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis.
Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Tenon Medical, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 27, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Steven Foster |
Contact Details
Address: 104 Cooper Court Los Gatos, California 95032 United States | |
| Phone | 408 649 5760 |
| Website | tenonmed.com |
Stock Details
| Ticker Symbol | TNON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1560293 |
| CUSIP Number | 88066N303 |
| ISIN Number | US88066N3035 |
| Employer ID | 45-5574718 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Foster | Chief Executive Officer, President and Director |
| Richard M. Ferrari | Founder and Executive Chairman |
| Richard Ginn | Founder, Chief Technology Officer, Chief Operating Officer and Director |
| Kevin Williamson | Chief Financial Officer and Secretary |
| Steve Moscaret | General Manager of Marketing and Sales Operation |
| Nathaniel A. Grawey | Chief Commercial Officer |
| Wyatt Drake Geist | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 8-K | Current Report |
| Jun 12, 2026 | PRE 14A | Other preliminary proxy statements |
| Jun 11, 2026 | 8-K | Current Report |
| May 22, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 19, 2026 | D/A | Filing |
| Mar 18, 2026 | D | Notice of Exempt Offering of Securities |